Phase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 1, 2001, Pages 93-102

  Crombet Ramos, Tania ^a   Torres, Olga ^a   Neninger, Elia ^b   Catalaá, Mauricio ^c   Rodríguez, Nelson ^c   Ramos, Mayra ^a   Fernández, Eduardo ^d   Iznaga, Normando ^a   Peérez, Rolando ^a   Lage1, Agustin ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^c Medical Surgical Research Center   (Cuba)

^d UNIVERSITY OF HAVANA   (Cuba)

Author keywords

Epidermal growth factor receptor; Immunotherapy; Monoclonal antibody; Phase I clinical trial; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IOR EGF R3; NEUTRALIZING ANTIBODY; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; DIAGNOSTIC ACCURACY; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIUM TUMOR; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HYPOTENSION; IMMUNOSCINTIGRAPHY; LETHARGY; LUNG CARCINOMA; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, HETEROPHILE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; CARCINOMA; COHORT STUDIES; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; HYPOTENSION; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; NEUTRALIZATION TESTS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SAFETY; SPECIES SPECIFICITY; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0035078409     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801750096122     Document Type: Article

References (53)

1. The Epidermal Growth Factor Receptor and its inhibition in cancer therapy
2. Epidermal growth factor receptor immunoreactivity in human laryngeal squamous cell carcinoma
3. Alterations of oncogenes tumor suppressor genes and growth factors in hepatocellular carcinoma with relation to tumor size and invasiveness
4. Role of epidermal growth factor receptor overexpression K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer
5. Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor
6. Immunohistochemistry of biomolecular markers of lung cancer
7. A multifactorial approach including tumoral epidermal growth factor receptor p53 thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
8. Tumor epidermal growth factor receptor erbB-2 and cathepsin D in node-negative invasive breast cancer: Their impact on the selection of patients for systemic adjuvant therapy
9. Antisense oligonucleotides to the epidermal growth factor receptor
10. Molecular pathogenesis of malignant gliomas
11. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer
12. Epidermal growth factor receptor expression: Predictive value for the outcome after cystectomy for bladder cancer
13. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma
14. Prognosis of esophageal squamous cell carcinoma: Analysis of clinicopathological and biological factors
15. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53 E-cad-herin epidermal growth factor receptor)
16. Expression of epidermal growth factor receptor family proteins (EGFR c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis
17. EGF TGF alpha and EGFR in human colorectal adenocarcinomas
18. Evidence for a role of EGF receptor in the progression of human lung carcinoma
19. Human lung cancers growing on extracellular matrix: Expression of oncogenes and growth factors
20. Mechanisms of lung oncogenesis
21. The prognostic importance of cancer-associated proteins and apoptosis in glioblastomas of the cerebral hemispheres
22. Iodine 125 labeled anti Epidermal Growth Factor Receptor 425 in the treatment of malignant astrocytomas. A pilot study
23. Malignant astrocytomas treated with iodine 125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial
24. Indium 111 labeled anti EGF-R 425 scintigraphy in the detection of malignant gliomas
25. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55, 900) in patients with recurrent malignant gliomas
26. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
27. Intratumoral infusions of the monoclonal antibody mAb 425 against the epidermal growth factor receptor in patients with advanced malignant gliomas
28. Phase I and imaging trial of Indium 111 labeled anti-EGFR monoclonal antibody 225 in patients with squamous cell lung carcinoma
29. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against Epidermal Growth Factor Receptor and Placental Alkaline Phosphatase
30. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852
31. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
32. Generación y caracterización primaria de anticuerpos monoclonales contra el receptor de EGF
33. A new monoclonal antibody for detection of the EGF-R in Western Blot and paraffin embedded tissue sections
34. Growth inhibition of human lung adenocarcinoma cells by antibodies against EGF-R and by ganglioside GM3
35. Diagnosis of tumors of epithelial origin with 99mTc-labeled murine monoclonal antibody ior egf/r3
36. 99mTC labeled Anti-human EGF-R in patients with tumours of epithelial origin. Clinical Trial Safety and Diagnostic Efficacy
37. 99mTc-Labeled-anti-human epidermal growth factor receptor antibody (ior egf/r3) in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy
38. 99mTc Anti-epidermal Growth Factor Receptor Antibody in patients with tumors of epithelial origin: Part I. Pharmacokinetics and clearances
39. Micromethod for quantification of SH groups generated after reduction of monoclonal antibodies
40. A novel approach to Tc-99m-labeled monoclonal antibodies
41. Technetium-99mTc direct radiolabeling of monoclonal antibody ior egf/r3
42. Estudios sobre el factor de crecimiento epidérmico (EGF) II: Desarrollo de un radioreceptor analisis para la determinación de cantidades picomolares
43. Harmonisation in pharmacovigilance
44. Posterior probabilities for choosing regression models
45. Statement of the clinical oncologic problem
46. 111 ln
47. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
48. Epidermal growth factor receptor in mice and men-any applications to clinical practice
49. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
50. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
51. Humanization of a mouse monoclonal antibody that blocks the EGF-R: Recovery of antagonistic activity